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Abstract: A powerful method for the synthesis of 2-oxazolines from silyl-protected β-
hydroxyamides is reported. Using diethylaminosulfur trifluoride (DAST) or its tetrafluoroborate salt 
(XtalFluor-E), silyl-protected β-amidoalcohols can be in situ deprotected and dehydrated to give 2-
oxazolines in good yields. The utility of this approach was demonstrated by preparing the first reported 
oligomer of [2,4']-coupled 2-oxazoline units. By tuning the stability of the silyl protecting groups (ex. 
IPDMS < TES < TBS, etc.), the deprotection rate can be optimized so that all reaction intermediates 
remain soluble, allowing cyclodehydration to occur at all potential sites of ring closure. N-terminal Ser 
residues containing an Fmoc carbamate are converted into 2-(9'-fluorenylmethyloxy)-2-oxazoline in 
high yield, thereby providing a new pathway for the synthesis of peptides capped with an N-terminal 2-
alkoxy-2-oxazoline or 2-oxazolidinone unit. 
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Introduction 
The discovery of oxazoline-containing bioactive natural products spawned widespread interest in 
the stereoselective synthesis of 2-oxazolines.[1] One common approach to this is the cyclodehydration 
of β-hydroxyamides.[2] While simple dehydrating reagents can be used (ex. PCl5, POCl3, COCl2, etc.), 
they exhibit low functional group compatibility and can cause epimerization of the α position. In 1968, 
Burgess et al. reported methyl N-(triethylammoniumsulfonyl)-carbamate, a mild dehydrating agent 
used for the elimination of secondary and tertiary alcohols.[3,4] Wipf and others utilized this reagent for 
the stereoselective cyclodehydration of β-hydroxyamides and thioamides.[5,6,7] The Burgess reagent, 
however, exhibits limited functional group tolerance, high moisture sensitivity, and a short shelf-life 
even when it is stored at low temperature.[8] Diethylaminosulfur trifluoride (DAST) is a commercially-
available fluorinating agent that can be used to cyclodehydrate β-hydroxyamides in good yields and 
with little or no epimerization of the α-position.[9] Recently, diethylaminodifluorosulfinium tetra-
fluoroborate (XtalFluor-E),[10] has been reported as an attractive alternative to DAST, due to its en-
hanced thermal stability and reduced side product formation.[11] One drawback to the use of these 
common cyclodehydration reagents is that a relatively inert, apolar solvent must be used for cyclode-
hydration, most commonly CH2Cl2.[9-11] The inability of such solvents to solubilize large, polar mole-
cules limits the scope of these reactions. This can be evidenced by the conspicuous absence of reported 
oligomers of [2,4']-coupled 2-oxazolines that, at least conceptually, could be prepared via dehydration 
of Serine oligomers. We speculated that the solubility of such peptides in apolar solvents could be 
dramatically improved by protecting the Serine residues as silyl ethers, and that the fluoride ions gen-
erated during the course of the reaction would remove the silyl protective groups in situ, allowing for 
cyclodehydration to occur (Scheme 1). Such “direct” conversions of silyl ethers into other functional 
groups including aldehydes,[12] bromides,[13] acetates,[14] and one example of a 2-oxazoline have been 
previously demonstrated using similar approaches.[15] 
Herein we report a method for the synthesis of 2-oxazolines by combining silylated β-
hydroxyamides with DAST or XtalFluor-E to facilitate in situ desilylation and cyclodehydration of β-
hydroxyamides under standard reaction conditions (Scheme 1). By tuning the stability of the silyl pro-
tecting group (e.g. IPDMS < TES < TBS, etc.), the rate of deprotection can be modulated so that it is 
slower than cyclodehydration, yet faster than undesirable side reactions (Scheme 2). This feature al-
lows intermediates to remain soluble during the course of the reactions, so that cyclodehydration can 
occur at all potential sites within large, polar peptides containing multiple serine residues.  
 
Scheme 1. In situ desilylation and cyclodehydration of β-hydroxyamides by DAST or XtalFluor-E.  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Proposed reaction pathway for the cyclodehydration of a silyl-protected β-hydroxyamide by 
XtalFluor-E. 
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Results and Discussion 
Cyclodehydration of silyl-protected β-hydroxyamides. 
To evaluate the impact of silyl group identity on cyclodehydration efficiency, the benzoylated serine 
methyl ester 1 was protected using isopropyldimethylsilyl chloride (IPDMS-Cl), triethylsilyl chloride 
(TES-Cl), tert-butyldimethylsilyl chloride (TBS-Cl), thexyldimethylsilyl chloride (TDS-Cl), triisopro-
pylsilyl chloride (TIPS-Cl), or tert-butyldiphenylsilyl chloride (TBDPS-Cl) to give compounds 2 – 7 in 
isolated yields ranging from 70 – 98% (Scheme 3). Trimethylsilyl (TMS) was not included in this se-
ries due to the low stability of TMS ethers.[16] Compounds 1 – 7 were reacted with 2 eq. XtalFluor-E in 
CH2Cl2 at rt for 24 h. Consistent with previous studies,[9-11] the unprotected alcohol 1 was converted 
into oxazoline 8 with a good isolated yield of 81%. The use of silyl-protected β-hydroxyamides con-
taining IPDMS (2) or TES (3) also provided 8 in good yields of 87% and 85%, respectively. The larger 
silyl groups present in 4 – 7, caused dramatically lower yields ranging from 16 – 49% of 8. According 
to HPLC and TLC analyses, compounds containing TDS (5), TIPS (6), and TBDPS (7) were not fully 
deprotected, as starting materials were still present in these mixtures after 24 h. Deprotection was com-
plete for the TBS derivative (4), but a mixture of alcohol 1 and oxazoline 8 was obtained, suggesting 
that XtalFluor-E decomposed over the course of the reaction with a rate similar to that of TBS depro-
tection.  
 
 
 
 
 
 
 
Scheme 3. Synthesis of silyl-protected β-hydroxyamides 2 – 7. 
 
 
 
 
 
 
 
Table 1. Cyclodehydration of 1 – 7 using XtalFluor-E. 
 
 
 
Compound “R” Yield of 8 [%] Notes 
1 H 81  
2 IPDMS 87  
3 TES 85  
4 TBS 41 a 
5 TDS 45 b 
6 TIPS 49 b 
7 TBDPS 16 b 
a Complete removal of silyl group after 24 h.  
b Remaining starting material observed after 24 h. 
 
To evaluate the relative rates of product formation, compounds 1 – 7 were reacted with 2 eq. 
XtalFluor-E in CH2Cl2 at rt, and aliquots from each reaction were removed as a function of time, 
quenched with MeOH, and analyzed by quantitative HPLC (Figure 1). Under these conditions, the un-
protected alcohol 1 is rapidly converted to oxazoline 8, giving a 60% conversion after only 120 sec-
onds, with an initial slope from 0 – 30 seconds ≈ 1.1 nmol / sec. The silyl protected substrates 2 and 3 
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exhibited a delay of roughly 50 s before any product formation could be observed. After this initiation 
period, the IPDMS-protected compound 2 gave a rapid rate of product formation (slope ≈ 0.58 nmol / 
sec), nearly that of the free alcohol 1 (slope ≈ 1.1 nmol / sec). The TES-protected compound 3, in con-
trast, exhibited a significantly lower rate of product formation (slope  ≈ 0.22 nmol / sec). The lower 
rates exhibited by 2 and 3 did not negatively impact the yields of these reactions, giving similar % con-
versions for compounds 1 – 3 after 10 min. Substrates 4 – 7, in contrast, exhibited dramatically lower 
cyclodehydration rates (slopes ≈ 0.004 – 0.015 nmoles / sec), consistent with the lower isolated yields 
from these reactions after 24 h (Table 1). The overall reaction rates for compounds 2 – 7 (IPDMS > 
TES >> TBS > TIPS > TDS > TBDPS) follow the known trends for nucleophilic substitution rates on 
silicon.[17] A 20-fold lower conversion rate was observed for 4 as compared to 2, which is consistent 
with the general differences in SN2 reaction rates for branched haloalkanes containing tBu versus iPr 
groups at the β-position.[18] In summary, these results demonstrate the feasibility of in situ desilylation 
and cyclodehydration of large polar molecules, where the triethylsilyl ether (TES) derivative 3 exhib-
ited a markedly slower rate for deprotection as compared to the subsequent cyclodehydration reaction. 
This feature should prevent the accumulation of insoluble alcohol/alkoxide groups during the course of 
cyclodehydration reactions on substrates that contain multiple sites of ring closure. Importantly, the 
lower cyclodehydration rate for 3 did not negatively impact the isolated yield for its conversion into 
oxazoline 8 (Table 1). We therefore selected TES for further development of this methodology in the 
context of di- tri- and penta-peptides.        
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Figure 1. Percent conversion of compounds 1 – 7 into oxazoline 8 according to quantitative analytical 
HPLC analysis of crude reactions containing 75 – 95 nmoles of 1 – 7 and XtalFluor-E (2 eq) in 2 mL 
of CH2Cl2 at rt. 
 
 
Cyclodehydration of β−substituted-hydroxyamides. 
To evaluate the SN2 character of the proposed ring-closing step (Scheme 2), cyclodehydration reac-
tions were conducted on the threonine-derivative 9 and its TES-protected analogue 10 using XtalFluor-
E and DAST. Good-to-excellent yields for the formation of a single 2-oxazoline diastereomer (accord-
ing to NMR, see Supporting Information) were obtained for all four reactions. The specific rotation 
( , in deg dm−1cm3 g−1) of the products were compared to literature values of + 96.7 for (R,S)-11 
and + 69.4 for (S,S)-11,[19] to reveal formation of (S,S)-11 (Table 2). These results indicate that an in-
version of configuration occurred during the cyclodehydration reactions of both silylated and non-
silylated substrates, consistent with an SN2-like ring closing mechanism (Scheme 2). 
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Table 2. Inversion of configuration upon cyclodehydration of threonine derivatives.  
 
 
 
Entry Substrate R Reagent Yield [%]  Config.
1 9 H XtalFluor-E 85 67.0 (S,S) 
2 9 H DAST 89 60.4 (S,S) 
3 10 TES XtalFluor-E 88 62.1 (S,S) 
4 10 TES DAST 94 64.1 (S,S) 
 
Cyclodehydration of dipeptides: substrate scope. 
The functional group tolerance of DAST and XtalFluor-E has been previously reported,[9-11] but 
their compatibility with common protecting groups used in peptide chemistry including benzyl (Bn), 
trityl (Tr), and tert-Butyl carbamate (Boc) has not been fully investigated. Acid-labile protective groups 
like Tr and Boc are of particular concern,[20] due to the formation of HF during the course of cyclode-
hydration (Scheme 2). As model systems to evaluate the functional group compatibility of DAST and 
XtalFluor-E with 2-oxazoline formation, we prepared dipeptides 12 – 17 of the general formula Boc-
Ser(Bn)-Ser(TES/OH)-OMe and Boc-Cys(Bn/Tr)-Ser(TES/OH)-OMe (Scheme 4).    
 
Scheme 4. Silylation of dipeptides. 
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Paquin and coworkers previously demonstrated that XtalFluor-E can give excellent yields for 
cyclodehydration of simple β-hydroxyamides when the reactions were heated from rt to 90 °C.[11] 
When XtalFluor-E was mixed and heated with dipeptide 12 at rt, a complex mixture of decomposition 
products was observed by TLC, none of which corresponded to the desired product 18 (“n.o.”, Table 
3). To prevent decomposition, the reaction temperature was lowered prior to the addition of XtalFluor-
E. By mixing the components at 0 °C or -78 °C, followed by slow warming to rt, oxazoline 18 could be 
isolated in low-to-modest yields of 11% and 46%, respectively (Entries 2 and 3, Table 3).  
Couturier and co-workers previously demonstrated that the addition of base can improve the yields 
for deoxofluorination of simple alcohols and carbonyl compounds by XtalFluor-E,[10] but it was hith-
erto unknown how added base would affect cyclodehydration efficiencies. This could, in principle, 
result in increased fluoride concentrations to facilitate silyl deprotection, while protecting Boc, Bn, and 
Tr groups from HF-mediated cleavage.[20] Indeed, the inclusion of 1.5 eq. of triethyl amine (TEA) to 
reactions containing 12 and XtalFluor-E, increased the isolated yield of 18 to 59%. By using 1,8-
Diazabicyclo[5.4.0]undec-7-ene (DBU) the yield was further increased to 76%. Unfortunately, the use 
of base in both reactions caused epimerization, giving a mixture of diasteromers (Entries 4 and 5, Table 
3, see Supporting Information). Reactions lacking exogenous base that utilized DAST instead of 
XtalFluor-E furnished oxazoline 18 as a single diastereomer in an 85% isolated yield, representing a 
dramatic improvement as compared to the 46% obtained with XtalFluor-E (Entries 3 and 6, Table 3). 
No loss of the Boc or Bn groups was observed when using DAST, despite the fact that HF concentra-
tions were previously reported to be higher in DAST-containing reactions as compared to XtalFluor-
E.[10] These results suggest that the higher Lewis acidity of XtalFluor-E as compared to DAST might 
cause compatibility problems with certain acid-labile protecting groups. The results obtained using 
SBn and STr groups support this notion vide infra (Tables 4 and 5).   
 
Table 3. Cyclodehydration of Boc-Ser(Bn)-Ser(TES/OH)-OMe. 
 
 
 
Entry Substrate R Reagent T [°C] Base Yield [%] 
1 12 H XtalFluor-E rt -   n.o.a 
2 12 H XtalFluor-E 0 to rt - 11 
3 12 H XtalFluor-E -78 to rt - 46 
4 12 H XtalFluor-E -78 to rt NEt3  59b 
5 12 H XtalFluor-E -78 to rt DBU  76b 
6 12 H DAST -78 to rt - 85 
7 15 TES XtalFluor-E -78 to rt - 56 
8 15 TES DAST -78 to rt - 89 
a “n.o.” = no observed product, decomposition of starting material 
b mixture of diastereomers obtained 
  
Having optimized the yields for cyclodehydration of the alcohol-containing Ser-Ser dipeptide 12, 
we next applied these conditions to the cyclodehydration of the TES-silylated peptide 15. The presence 
of the TES group had a small, yet consistently positive effect, on the isolated yields of oxazoline 18 
that ranged from 56 – 89% (Entries 7 – 8, Table 3). These yields represent improvements in the range 
of 4 – 10% as compared to the yields obtained for the corresponding free alcohol 12 (Entries 3 and 6). 
Larger improvements upon silylation were observed for Cys-Ser dipeptide and (Ser)3 tripeptides (Ta-
bles 4 – 6). In all cases, fewer byproducts were generated when using the silylated peptides, thereby 
facilitating product purification. 
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Table 4. Cyclodehydration of Boc-Cys(Bn)-Ser(TES/OH)-OMe. 
 
 
 
Entry Substrate R Reagent T [°C] Base Yield [%] 
1 13 H XtalFluor-E rt -  n.o.a 
2 13 H XtalFluor-E 0 to rt -  n.o.a 
3 13 H XtalFluor-E -78 to rt - 44 
4 13 H XtalFluor-E -78 to rt DBU  50b 
5 13 H DAST -78 to rt - 61 
6 16 TES XtalFluor-E -78 to rt - 55 
7 16 TES XtalFluor-E -78 to rt DBU  60b 
8 16 TES DAST -78 to rt - 67 
a “n.o.” =  no observed product, decomposition of starting material 
b mixture of diastereomers obtained 
 
Cysteine is an important synthetic precursor of thiazole and thiazolinum,[21] but the compatibility of 
sulfur-containing peptides with DAST and XtalFluor-E is potentially problematic,[10] and peptides con-
taining fused Cysteine-oxazoline units are only rarely reported.[22] Peptide 13 contains a Cys(Bn)-
Ser(TES/OH) unit and was highly susceptible to decomposition at rt in reactions containing XtalFluor-
E  (Entries 1 and 2, Table 4). By starting the reaction at -78 °C, a 44% isolated yield of oxazoline 19 
could be obtained (Entry 3). The addition of DBU improved the yield to 50%, but epimerization was 
again observed (Entry 4). Reacting 13 with DAST yielded 19 in 61% as a single diastereomer (Entry 6, 
Table 4). Approximately 10% higher yields were obtained in these reactions when using the silylated 
peptide 16 (Entries 6 – 8) as compared to the free alcohol 13 (Entries 3 – 6, Table 4).  
In general, C-S bonds are about 20 kcal mol-1 weaker than C-O bonds,[23] and are therefore more 
susceptible to cleavage by Lewis and Brønsted acids.[17] Accordingly, the yields obtained for the 
Cys(Bn)-containing peptides 13 and 16 (Table 4), were consistently lower than for the corresponding 
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Ser(Bn)-containing peptides 12 and 15 (Table 3). The highly labile trityl protective group (Tr) was 
even more problematic in the context of peptides 14 and 17 that contain a Cys(Tr) residue. Upon addi-
tion of XtalFluor-E, peptide 14 immediately decomposed in reactions maintained at 0 °C or above, 
giving an intensely-colored yellow solution (Entry 1, Table 5). When the temperature of the reaction 
was maintained at -78 °C, 12% of oxazoline 20 could be obtained from a complex mixture of decom-
position products (Entry 2, Table 5). A slightly higher yield of 39% was obtained by including DBU in 
the reaction, but epimerization was observed (Entry 3, Table 5). At -78 °C, the reaction of 14 with 
DAST yielded 79% of the desired product as a single diastereomer (Entry 4, Table 5). A slightly higher 
yield of 85% was obtained when using the corresponding TES-protected peptide 17, upon warming the 
reaction to 0 °C to facilitate deprotection of the silyl group (Entry 5, Table 5). Under the same condi-
tions, the reaction of XtalFluor-E with TES-protected peptide 17 gave a complex mixture of decompo-
sition products containing little or no of the desired product (Entry 6, Table 5). Together, these results 
demonstrate that TES-protected Ser units in Cys-Ser dipeptides can serve as efficient oxazoline precur-
sors, especially in cases where DAST is used as the cyclodehydrating reagent.  
 
 
 
 
 
 
 
 
 
 
 
Table 5. Cyclodehydration of Boc-Cys(Tr)-Ser(TES/OH) dipeptide. 
 
 
 
Entry Substrate R Reagent T [°C] Base Yield [%] 
1 14 H XtalFluor-E 0 to rt -  n.o.a 
2 14 H XtalFluor-E - 78 - 12 
3 14 H XtalFluor-E - 78 DBU  39b 
4 14 H DAST - 78 - 79 
5 17 TES DAST - 78 to rt - 85 
6 17 TES XtalFluor-E - 78 to rt -  n.o.a 
a “n.o.” =  no observed product, decomposition of starting material 
b mixture of diastereomers obtained.  
 
 
Scheme 5. Synthesis and silylation of Boc-Ser(Bn)-Ser(TES/OH)-Ser(TES/OH). 
 
 
 
 
 
 
 
 
 
Tandem [2,4']-coupled 2-oxazoline units can be prepared via cyclodehydration reactions of peptides 
containing multiple Serine residues.[21] We therefore compared the ability of XtalFluor-E and DAST to 
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generate two consecutive 2-oxazolines from peptides containing Ser(OH) or Ser(TES) residues. To 
provide starting material for these reactions, peptide 12 was elongated by one serine moiety in a two-
step procedure, where the methyl ester was hydrolyzed using LiOH in H2O/MeOH, followed by pep-
tide coupling with L-serine methyl ester hydrochloride to give an inseparable mixture of diastereomers. 
Silylation of tripeptide 21 was performed using TES-Cl and imidazole in DMF (81%). 21 was reacted 
with XtalFluor-E at -78 °C to give a 27% isolated yield of the desired products containing two con-
secutive 2-oxazoline units (Entry 1, Table 6). The reaction of tripeptide 21 with DAST at -78 °C gave a 
moderate yield of 53%, which could be further improved to 73% by utilizing the TES-protected peptide 
22. This improvement in yield was only observed when using DAST, and not in the case of XtalFluor-
E (Entries 3 and 4, Table 6). These reactions provide rare examples of simultaneous synthesis of two 
tandem [2,4']-fused 2-oxazoline units, and further demonstrate the potential advantages of using of 
silyl-protected Ser units in the starting material.       
 
Table 6. Cyclodehydration of Boc-Ser(Bn)-Ser(TES/OH)-Ser(TES/OH). 
 
 
 
Entry Substrate R Reagent T [°C] Base Yield [%] 
1 21 H XtalFluor-E -78 to rt - 27 
2 21 H DAST -78 to rt - 53 
3 22 TES XtalFluor-E -78 to rt - 12 
4 22 TES DAST -78 to rt - 73 
 
Cyclodehydration of β-hydroxycarbamates. 
Carbamates are ubiquitous groups in peptide synthesis, where tert-butoxycarbonyl (Boc), fluo-
renylmethyloxycarbonyl (Fmoc) and benzyl carbonate (Cbz) are used to protect the N-terminal amines.  
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It is well known that O-protected, N-terminal Serine residues containing Cbz or Boc remain stable in 
the presence of DAST, giving good to excellent yields for cyclodehydration reactions at remote β-
hydroxyamides (Tables 3 – 6).[9] However, little or nothing is reported about the reactivity of Boc, Cbz, 
and Fmoc groups in the context of β-hydroxycarbamates, where the N-terminal Ser residue carries a 
free alcohol. In this case, cyclodehydration could conceivably furnish 2-alkoxy-2-oxazolines. In gen-
eral, only a few methods have been reported for the synthesis of 2-alkoxy-2-oxazolines,[24] most com-
mon is the O-alkylation of 2-oxazolidinones to give 2-ethoxy[25] and 2-benzoxyoxazolines.[26] To inves-
tigate the potential synthesis of N-terminal 2-alkoxy-2-oxazolines from β-hydroxycarbamates, sub-
strates 24 – 28 were prepared and reacted with DAST or XtalFluor-E (Table 7).  
 
Table 7. Cyclodehydration of carbamates using XtalFluor-E and DAST. 
 
 
 
 
Entry Substrate Carbamate R2 Product Reagent T [°C] Yield [%]
1 24 Boc H 29 XtalFluor-E rt   n.o.a 
2 24 Boc H 29 DAST -78   n.o.a 
3 25 Cbz H 30 XtalFluor-E -78 16 
4 25 Cbz H 30 DAST - 78   n.o.a 
5 26 Cbz TES 30 DAST -78 to rt   n.o.a 
6 27 Fmoc H 31 XtalFluor-E -78 45 
7 27 Fmoc H 31 DAST -78 61 
8 28 Fmoc TES 31 DAST -78 to rt 71 
a “n.o.” = no observed product, decomposition of starting material  
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Boc-protected carbamate 24 was reacted with XtalFluor-E at rt or at -78 °C, but no oxazoline 29 
could be observed by TLC or ESI-MS. The reaction of Cbz-protected 25 with XtalFluor-E gave oxa-
zoline 30 in a 16% isolated yield, while the reaction of TES-protected 27 with DAST gave a complex 
mixture of products containing no detectable product. The cyclodehydration of Fmoc-protected 27 us-
ing XtalFluor-E and DAST gave 31 in 45% and 61% isolated yields, respectively. When using the 
TES-protected derivative 28, the isolated yield of 31 increased to 71% with little or no byproduct for-
mation. These results demonstrate suggest that N-terminal Fmoc/TES-protected Serine residues are 
especially well suited for cyclodehydration reactions to give an N-terminal 2-alkoxy-2-oxazoline. We 
therefore selected Fmoc as the N-terminal protecting group for the synthesis of oligomers containing 
[2,4']-coupled 2-oxazoline units. 
 
Cyclodehydration of (Ser)5 
Little is known about the synthesis or physical properties of linear oligomers of oxazoline units. 
The longest reported example is an intermediate from the total synthesis of Thiangazole, containing 
only three consecutive units.[21] To evaluate the synthesis of oxazoline oligomers by in situ desilylation 
and cyclodehydration of β-hydroxyamide oligomers, 32 was synthesized via Fmoc solid-phase synthe-
sis and isolated as a crude product in a 84% yield (Scheme 6).  
 
Scheme 6. Solid phase peptide synthesis of (Ser)5 32. 
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Crude peptide 32 was protected on each termini and silylated in a three step procedure to obtain 
silylated pentaserine 33 (Scheme 7). The N-terminal amine was protected using Fmoc-Cl and NaHCO3 
in a MeOH/H2O (1:2) solution. After the protection was complete, the product was precipitated using 
DCM and directly used for the esterification. The methyl ester was formed by adding excess TMS-Cl 
to a stirring suspension of the crude material in MeOH. The product was again precipitated and directly 
used for the silylation. Reaction with TES-Cl in pyridine and purification by silica gel column chroma-
tography provided pure peptide 33 in a 22% isolated yield over three steps.  
Scheme 7. Synthesis of silyl-protected Fmoc-(Ser)5 33 and its cyclodehydration to 34. 
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Peptide 33 was reacted with 15 eq. DAST at -78 °C in DCM and slowly warmed to 0 °C over 4 
h, during which 33 and all reaction intermediates remained soluble.[27] The reaction was then quenched 
with MeOH and purified by silica gel column chromatography. Pentaoxazoline 34 was thereby ob-
tained in a 34% isolated yield as a single diastereomer, representing a >80% yield for cyclodehydration 
at each independent position. This molecule represents the first example of a linear oligomer of oxa-
zoline containing more than three units, and it contains a novel, N-terminal 2-(9'-fluorenylmethyloxy)-
2-oxazoline.  
 
Conclusions 
We have developed a method to synthesize 2-oxazolines from silyl-protected β-amido alcohols in a 
tandem two-step reaction comprising deprotection and cyclodehydration upon addition of a de-
oxofluorinating agent. After screening various silyl groups, we found that triethylsilyl (TES) was opti-
mal, giving a rate of deprotection that was significantly slower than the cyclodehydration reaction. This 
prevents accumulation of highly polar and insoluble alcohol/alkoxide groups during the course of 
cyclodehydration reactions on substrates containing multiple sites of ring closure. This provides a 
means to synthesize 2-oxazolines from highly polar starting materials that would otherwise be insolu-
ble under standard reaction conditions. As a demonstration, we synthesized the first oxazoline oligomer 
containing five linear units from a Fmoc-(Ser)5 peptide. During the course of the reaction, the N-
terminal F-moc protected Ser residue was converted into a 2-(9'-fluorenylmethyloxy)-2-oxazoline unit, 
thereby revealing a new pathway for the synthesis of peptides capped with an N-terminal 2-alkoxy-2-
oxazoline, or following deprotection, a 2-oxazolidinone unit.[28]  
 
 
 
Experimental Section 
General Information: Starting materials were obtained in the highest commercial grades and used 
without further purification. All reactions sensitive to moisture and/or air were carried out under an 
atmosphere of argon or nitrogen in dry, freshly distilled solvents under anhydrous conditions using 
oven-dried glassware. Commercially-available dichloromethane (CH2Cl2) was purified by distillation 
prior to use. Commercially-available anhydrous pyridine was used directly without further drying. For 
all aq. solutions, H2O was purified on a Purelab Ultra MK2 apparatus from ELGA Labwater. Analyti-
cal thin-layer chromatography was performed on precoated 250 µm layer thickness silica gel 60 F254 
plates. Visualization was performed by ultraviolet light and staining with a KMnO4-solution. Flash 
column chromatography was performed using 40−63 µm silica gel using compressed air. 1H-NMR 
spectra were recorded on 300, 400, and 500 MHz spectrometers; tetramethylsilane or the residual sol-
vent peaks were used as internal standards: DMSO (quint, δH = 2.50 ppm), CHCl3 (s, δH = 7.26 ppm). 
13C NMR spectra were recorded on 75, 100, and 125 MHz spectrometers, with δ relative to DMSO (δ 
40.5 ppm) or CHCl3 (δ 77.23 ppm). Coupling constants (J) are reported in hertz (Hz). The following 
abbreviations were used to explain the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m 
= multiplet, dd = doublet−doublet, ddd = doublet−doublet−doublet, dt = doublet−triplet, br = broad. 
Mass spectra were obtained on a quadrupole ion trap instrument equipped with a atmospheric pressure 
ion (API) source. High-resolution electrospray mass spectra (HR-ESI MS) were recorded on a 
QTOFMS instrument. Infrared spectra were recorded on a FTIR spectrometer. Optical rotation ( ) 
was measured at room temperature with a PerkinElmer 241MC Polarimeter and values are given in deg 
cm3 g-1 dm-1, concentration c is given in g (100 ml)-1. 
Synthesis of hydroxyamide derivatives. General Procedure A.[29] To a stirring solution of amine 
(1 mmol) in EtOH at rt, the carboxylic acid (1.03 mmol), NMM (2.2 mmol) and HOBt (0.15 mmol) 
were subsequently added. The solution was then cooled to 0 °C and EDC (1.2 mmol) was added. The 
reaction was stirred at rt overnight, followed by the addition of 0.1 M citric acid. The mixture was then 
extracted with EtOAc (3x). The combined organic phases were extracted with brine (1x), dried over 
anhydrous MgSO4, filtered, and concentrated in vacuo. The crude material was purified by column 
chromatography to give the indicated product. 
Synthesis of silylated hydroxyamide derivatives. General Procedure B.[30] To a stirring solution 
of the hydroxyamide derivative (1 mmol) in DMF or DCM, the corresponding silyl-chloride (1.3 – 3 
mmol) was added at rt. After stirring for 30 min, imidazole or NEt3 (2 – 5 mmol) was added and stirred 
over night. The solution was diluted with EtOAc and washed with 0.1 M citric acid and brine, dried 
over MgSO4, filtered, and concentrated in vacuo. The crude material was purified by column chroma-
tography to give the desired product. 
Synthesis of 2-oxazolines via cyclodehydration. General Procedure C. To a stirring solution of 
β-hydroxyamide or silylated β-hydroxyamide (1 mmol) in DCM (2 ml), DAST or XtalFluor-E (2 – 3 
mmol) and DBU or NEt3 (1.5 mmol, optionally) were added. The solution was then stirred at -45 °C or 
-78 °C and allowed to warm to 0 °C or rt. After completion, the reaction was quenched by sat. NaHCO3 
in MeOH or MeOH and dried using a rotary evaporator. The crude material was purified by column 
chromatography to give the desired product.  
N-Benzoyl-(S)-serine methyl ester (1). To a suspension of HCl●Ser-OMe (3.00 g, 19.28 mmol) at 
0°C in CH2Cl2 (50 ml) was added a solution of Bz-Cl (2.50 ml, 21.50 mmol) in CH2Cl2 (20 ml) and 
successively a solution of NEt3 (5.40 ml, 38.96 mmol) in CH2Cl2 (30 ml) over a period of 20 m. The 
reaction mixture was kept under 4 °C for 2 h and allowed to slowly warm to rt. After completion, 0.1 
M citric acid was added. The resulting solution was extracted with DCM (3x) and the combined or-
ganic layers were washed with brine (1x), dried over MgSO4, filtered, and evaporated in vacuo. The 
crude material was subjected to column chromatography on silica gel (hexane/EtOAc, gradient from 
2:1 to 1:2) to give a white solid which was recrystallized (hexane/CH2Cl2, 1:1) to give 1 as white nee-
dles (2.61 g, 11.68 mmol, 61%): Rf (hexane/EtOAc, 1:1) 0.21; IR (neat) ν = 3349, 2953, 1739,  1639, 
1578, 1528, 1488, 1442, 1348, 1209, 1160, 1073, 713, 691, 530 cm-1; 1H-NMR (300 MHz, CDCl3) δ 
7.81 (d, J = 9.0, 2 H), 7.51 (t, J = 6.0, 1 H), 7.42 (t, J = 6.0, 2 H), 7.12 (d, J = 6.0, 1H), 4.87-4.84 (m, 
1H), 4.09-3.99 (m, 2H), 3.80 (s, 3H), 2.49 (s, 1H); 13C-NMR (75 MHz, CDCl3) δ 171.3, 167.9, 133.6, 
132.2, 128.9, 127.4, 63.8, 55.4, 53.1; HRMS (ESI-TOF) m/z: [M+Na]+ calculated for C11H14NO4Na 
246.0737, found 246.0734. 
N-Benzoyl-O-((1-methylethyl)dimethylsilyl)-(S)-serine methyl ester (2). Following general pro-
cedure B on a 2.24 mmol scale of 1 using IPDMS-Cl (453 µl, 2.69 mmol) and imidazole (305 mg, 4.48 
mmol) in DMF (1 ml), the desired product (714 mg, 2.21 mmol, 98%) was isolated as colorless oil by 
extraction: Rf (hexane/EtOAc, 3:1) 0.57; IR (neat) ν = 3448, 3333, 2953, 2865, 1745, 1653, 1518, 
1486, 1348, 1302, 1251, 1207, 1163, 1104, 999, 883, 829, 776, 712, 691, 520 cm-1; 1H-NMR (300 
MHz, CDCl3) δ 7.81 (d, J = 6.0, 2 H), 7.56-7.43 (m, 3 H), 6.97 (d, J = 7.8, 1 H), 4.87 (dt, J = 1.8, 8.1, 1 
H), 4.15 (dd, J1 = 2.7, J2 = 10.2, 1 H), 3.95 (dd, J1 = 3.0, J2 = 10.0, 1 H), 3.79 (s, 3 H), 0.93 (d, J = 6.3, 
6H), 0.88-0.79 (m, 1H), 0.04 (s, 6 H); 13C-NMR (75 MHz, CDCl3) δ 171.2, 167.2, 134.2, 131.9, 128.8, 
127.3, 63.4, 54.8, 52.7, 16.9, 14.5, -4.4; HRMS (ESI-TOF) m/z: [M+Na]+ calculated for 
C16H25NO4SiNa 346.1445, found 346.1446. 
N-Benzoyl-O-(triethylsilyl)-(S)-serine methyl ester (3). Following general procedure B on a 2.24 
mmol scale of 1 using TES-Cl (451 µl, 2.69 mmol) and imidazole (305 mg, 4.48 mmol) in DMF (1 ml) 
the desired product (679 mg, 2.00 mmol, 90%) was isolated as a colorless oil by silica gel column 
chromatography: Rf (hexane/EtOAc, 9:1) 0.21; IR (neat) ν = 3448, 3333, 2953, 2911, 2876, 1746, 
1655, 1516, 1485, 1465, 1350, 1296, 1243, 1207, 1163, 1104, 1004, 973, 814, 712 cm-1; 1H-NMR (300 
MHz, CDCl3) δ 7.79 (d, J = 6.0, 2 H), 7.53-7.41 (m, 3 H), 6.98 (d, J = 6.0, 1 H), 4.86 (dt, J = 3.0, 9.0, 1 
H), 4.15 (dd, J1 = 3.0, J2 = 12.0, 1 H), 3.95 (dd, J1 = 3.0, J2 = 12.0, 1 H), 3.77 (s, 3 H), 0.91 (t, J = 6.0, 
9H), 0.56 (q, J = 6.0, 6H); 13C-NMR (75 MHz, CDCl3) δ 171.2, 167.2, 134.2, 132.0, 128.8, 127.3, 
63.5, 54.9, 52.7, 6.8, 4.4; HRMS (ESI-TOF) m/z: [M+Na]+ calculated for C17H27NO4SiNa 360.1602, 
found 360.1600. 
N-Benzoyl-O-((tert-butyl)-dimethylsilyl)-(S)-serine methyl ester (4). Following general proce-
dure B on a 4.48 mmol scale of 1 using TBS-Cl (960 µl, 5.38 mmol) and imidazole (762 mg, 11.99 
mmol) in DMF (2 ml), the desired product (1.23 g, 3.66 mmol, 82%) was isolated as a colorless oil by 
silica gel column chromatography (hexane/EtOAc, 6:1): Rf (hexane/EtOAc, 6:1) 0.55; IR (neat) ν = 
3442, 3333, 2953, 2929, 2856, 2348, 1745, 1653, 1518, 1486, 1471, 1436, 1385, 1350, 1302, 1253, 
1207, 1163, 1105, 1046, 833, 777, 712, 691, 666 cm-1; 1H-NMR (300 MHz, CDCl3) δ 7.83-7.80 (m, 2 
H), 7.50-7.45 (m, 3 H), 6.96 (d, J = 9.0, 1 H), 4.68-4.85 (m, 1 H), 4.16 (dd, J1 = 3.0,  J2 = 10.5, 1 H), 
3.96 (dd, J1 = 3.0, J2 = 9.0, 1 H), 3.78 (s, 3 H), 0.87 (s, 9H), 0.03 (s, 3 H), 0.03 (s, 3 H); 13C-NMR (75 
MHz, CDCl3) δ 171.8, 167.7, 134.6, 132.3, 129.2, 127.6, 63.7, 54.8, 52.5, 25.6, 18.0, 5.9, 5.8; HRMS 
(ESI-TOF) m/z: [M+Na]+ calculated for C17H27NO4SiNa 360.1602, found 360.1604. 
N-Benzoyl-O-((2,3-dimethyl-2-butyl)-dimethylsilyl)-(S)-serine methyl ester (5). Following gen-
eral procedure B on a 1.17 mmol scale of 1 using TDS-Cl (299 µl, 1.52 mmol) and imidazole (161 mg, 
2.34 mmol) in DMF (1 ml), the desired product (376 mg, 1.03 mmol, 89%) was isolated as a colorless 
oil by silica gel column chromatography (hexane/EtOAc, 6:1): Rf (hexane/EtOAc, 6:1) 0.61; IR (neat) 
ν = 3448, 3338, 2954, 2870, 1746, 1666, 1514, 1485, 1467, 1437, 1380, 1350, 1252, 1206, 1166,  1104, 
1040, 827, 777, 711, 691, 494 cm-1; 1H-NMR (300 MHz, CDCl3) δ 7.80 (d, J = 1.8, 2 H), 7.53-7.43 (m, 
3 H), 6.96 (d, J = 7.2, 1 H), 4.88 (dt, J = 2.7, 5.4, 1 H), 4.15 (dd, J1 = 3.0,  J2 = 10.0, 1 H), 3.95 (dd, J1 
= 3.0, J2 = 9.9, 1 H), 3.78 (s, 3 H), 1.64-1.55 (m, 1H), 0.87 (d, J = 6.9, 6 H), 0.83 (s, 6H), 0.1 (s, 6 H); 
13C-NMR (75 MHz, CDCl3) δ 171.2, 167.1, 134.3, 132.0, 128.9, 127.3, 63.7, 54.9, 52.7, 34.5, 25.3, 
20.4, 18.7, -3.5; HRMS (ESI-TOF) m/z: [M+Na]+ calculated for C19H31NO4SiNa 388.1915, found 
388.1913. 
N-Benzoyl-O-(triisopropyl)-(S)-serine methyl ester (6). Following general procedure B on a 4.51 
mmol scale of 1 using TIPS-Cl (1.11 ml, 5.67 mmol) and imidazole (765 mg, 11.18 mmol) in DMF (2 
ml), the desired product (1.19 g, 3.13 mmol, 70%)  was isolated as a colorless oil by silica gel column 
chromatography (hexane/EtOAc, 6:1): Rf (hexane/EtOAc, 3:1) 0.69; IR (neat) ν = 3442, 3333, 2943, 
2866, 2354, 1746, 1666, 1516, 1485, 1464, 1437, 1380, 1349, 1296, 1245, 1206, 1163, 1110, 1066, 
1040, 994, 881, 799, 735, 712, 683, 661 cm-1; 1H-NMR (300 MHz, CDCl3) δ 7.83-7.80 (m, 2 H), 7.50-
7.45 (m, 3 H), 7.03 (d, J = 9.0, 1 H), 4.91-4.86 (m, 1 H), 4.27 (dd, J1 = 3.0,  J2 = 6.0, 1 H), 3.96 (dd, J1 
= 3.0, J2 = 6.0, 1 H), 3.78 (s, 3 H), 1.07-0.99 (m, 21H); 13C-NMR (75 MHz, CDCl3) δ 171.8, 167.7, 
134.7, 132.3, 129.2, 127.6, 64.3, 54.8, 52.5,  17.7, 17.6, 11.6; HRMS (ESI-TOF) m/z: [M+Na]+ calcu-
lated for C20H33NO4SiNa 402.2071, found 402.2072. 
N-Benzoyl-O-(tert-butyldiphenylsilyl)-(S)-serine methyl ester (7). Following general procedure B 
on a 2.24 mmol scale of 1 using TBDPS-Cl (757 µl, 2.91 mmol) and imidazole (305 mg, 4.48 mmol) in 
DMF (1 ml), the desired product (925 mg, 2.00 mmol, 89%) was isolated as a white solid by silica gel 
column chromatography (hexane/EtOAc, 9:1): Rf (hexane/EtOAc, 3:1) 0.58; IR (neat) ν = 3442, 3338, 
2953, 2932, 2885, 2854, 1745, 1665, 1514, 1484, 1472, 1428, 1349, 1247, 1207, 1162 1106, 823, 736, 
700, 690, 613, 488 cm-1; 1H-NMR (300 MHz, CDCl3) δ 7.68-7.03 (m, 15H), 7.02 (d, J = 6.0, 1H), 4.20 
(dd, J1 = 3.0, J2 = 9.0, 1H), 4.01 (dd, J1 = 3.0, J2 = 9.0, 1H), 3.77 (s, 3H), 1.03 (s, 9H); 13C-NMR (75 
MHz, CDCl3) δ 171.0, 166.9, 135.5, 134.8, 133.9, 132.9, 131.8, 130.0, 129.6, 128.6, 127.8, 127.7, 
127.1, 64.5, 54.6, 52.6, 26.7, 19.3; HRMS (ESI-TOF) m/z: [M+Na]+ calculated for C27H31NO4SiNa 
484.1915, found 484.1919. 
(4S)-4-Methoxycarbonyl-2-phenyl-2-oxazoline (8). Following general procedure C on a 0.10 
mmol scale of 3 using XtalFluor-E (46 mg, 0.20 mmol) in CH2Cl2 and sat. NaHCO3 in MeOH to 
quench the reaction, the desired product (18 mg, 0.09 mmol, 87 %) was isolated as a colorless oil by 
silica gel column chromatography (hexane/EtOAc, 2:1): Rf (hexane/EtOAc, 1:1) 0.64;  +123.2 (c 
= 1.0, CHCl3) {(Lit.[31]  + 122.7 (c=1.0, CHCl3)}; IR (neat) ν = 2953, 1738, 1639, 1450, 1436, 
1360, 1296, 1272, 1203, 1176, 1088, 1068, 1059, 1039, 1025, 970, 945, 778, 693 cm-1; 1H-NMR (300 
MHz, CDCl3) δ 8.00-7.98 (m, 2 H, Ph), 7.52-7.48 (m, 1H, Ph), 7.43-7.40 (m, 2H, Ph), 4.96 (dd, J1 = 
8.0, J2 = 10.5, 1H, CHCH2O), 4.70 (dd, J1 = 8.0, J2 = 9.0, 1H, CH2O), 4.60 (dd, J1 = 8.5, J2 = 10.5, 1H, 
CH2O), 3.82 (s, 3H, OCH3); 13C-NMR (75 MHz, CDCl3) δ 171.8, 166.6, 132.1, 128.85, 128.6, 127.1, 
69.8, 68.8, 53.0; HRMS (ESI-TOF) m/z: [M+Na]+ calculated for C11H11NO3Na 228.0631, found 
228.0627. 
N-Bz-Thr-OMe (9). To a suspension of HCl●Thr-OMe (2.00 g, 11.6 mmol) at 0°C in CH2Cl2 (40 
ml), was added a solution of Bz-Cl (1.56 ml, 11.56 mmol) in CH2Cl2 (10 ml) and successively a solu-
tion of NEt3 (3.29 ml, 23.6 mmol) in CH2Cl2 (40 ml) over a period of 30 m. The reaction mixture was 
allowed to slowly warm up to rt overnight. After completion, 0.1 M citric acid was added. The result-
ing solution was extracted with DCM (3x) and the combined organic layers were washed with brine 
(1x), dried over MgSO4, filtered, and evaporated in vacuo. The crude material was subjected to column 
chromatography on silica gel (hexane/EtOAc, gradient from 2:1 to 1:2) to give 1 as a slightly yellow 
powder (2.64 g, 11.1 mmol, 96%): Rf (hexane/EtOAc, 1:1): 0.24; IR (neat) ν = 3375, 2974, 2359, 2333, 
1740, 1643, 1579, 1524, 1488, 1437, 1316, 1211, 1165, 1080, 1017, 1000, 927, 884, 838, 713, 691, 
665, 541, 412 cm-1; 1H-NMR (300 MHz, CDCl3) δ 7.85 (d, J = 6.0, 2H), 7.53-7.45 (m, 3H), 6.93 (br s, 
1H), 4.85-4.81 (m, 1H), 4.49-4.43 (m, 1H), 3.80 (s, 3H), 2.17 (br s, 1H), 1.29 (d, J = 6.0, 3H); 13C-
NMR (75 MHz, CDCl3) δ 172.4, 168.7, 134.4, 132.5, 129.2, 127.7, 68.5, 57.7, 52.8, 20.0; HRMS (ESI-
TOF) m/z: [M+Na]+ calculated for C12H15NO4Na 260.0893, found 260.0890. 
N-Bz-Thr(TES)-OMe (10). Following general procedure B on a 1.77 mmol scale of 1 using TES-
Cl (350 µl, 2.12 mmol) and NEt3 (320 µl, 2.30 mmol) in CH2Cl2 (5 ml), the desired product (522 mg, 
1.49 mmol, 84%) was isolated as a colorless oil by silica gel column chromatography (hexane/EtOAc, 
3:1): Rf (hexane/EtOAc, 3:1): 0.36; IR (neat) ν = 2954, 2913, 2876, 2361, 2335, 1748, 1670, 1513, 
1484, 1439, 1381, 1349, 1317, 1239, 1207, 1167, 1126, 1092, 1004, 963, 840, 712, 527, 465 cm-1; 1H-
NMR (300 MHz, CDCl3) δ 7.84 (d, J = 6.0, 2H), 7.54-7.44 (m, 3H), 6.85 (d, J = 9.0, 1H), 4.78-4.75 (m, 
1H), 4.60-4.53 (m, 1H), 3.76 (s, 3H), 1.26 (d, J = 6.0, 3H), 0.95 (t, J = 9.0, 9H), 0.59 (q, J = 9.0, 6H); 
13C-NMR (75 MHz, CDCl3) δ 172.0, 168.5, 134.9, 132.3, 129.2, 127.7, 69.1, 58.3, 52.4, 21.1, 6.5, 4.6; 
HRMS (ESI-TOF) m/z: [M+Na]+ calculated for C18H29NO4SiNa 374.1758, found 374.1762. 
(4S,5S)-4-Carboxymethoxy-5-methyl-2-phenyloxazoline (11). Following general procedure C on 
a 0.21 mmol scale of 1 using DAST (55 µl, 0.41 mmol) in CH2Cl2 and sat. NaHCO3 in MeOH to 
quench the reaction, the desired product (40 mg, 0.18 mmol, 89%) was isolated as a colorless oil by 
silica gel column chromatography (hexane/EtOAc, 3:1): Rf (hexane/EtOAc, 3:1): 0.41.  +60.36 (c 
= 0.92, CHCl3); IR (neat) ν = 2984, 2950, 2361, 2340, 1737, 1645, 1583, 1493, 1449, 1436, 1349, 
1244, 1197, 1174, 1082, 1066, 1044, 1027, 932, 841, 778, 734, 694, 491 cm-1; 1H-NMR (300 MHz, 
CDCl3) δ 7.99-7.96 (m, 2H), 7.47-7.36 (m, 3H), 5.10-5.02 (m, 1H), 4.97 (d, J = 10.2, 1H), 3.75 (s, 3H), 
1.36 (d, J = 6.0, 3H); 13C-NMR (75 MHz, CDCl3) δ 170.4, 166.5, 132.2, 128.7, 128.5, 78.0, 71.6, 52.3, 
16.4; HRMS (ESI-TOF) m/z: [M + Na]+ calculated for C12H13NO3Na 242.0788, found 242.0787. 
N-Boc-Ser(Bn)-Ser-OMe (12). Following general procedure A on a 5.57 mmol scale of HCl●Ser-
OMe using Boc-Ser(OBn)-OH (1.70 g, 5.74 mmol), EDC (1.29 g, 6.69 mmol), NMM (1.35 ml, 12.25 
mmol), and HOBt (112.93 mg, 0.84 mmol) in EtOH (20 ml), the desired product (1.96 g, 4.93 mmol, 
86%) was isolated as colorless oil by silica gel column chromatography (hexane/EtOAc, 3:1): Rf (hex-
ane/EtOAc, 1:1) 0.27; IR (neat) ν = 3342, 2978, 2354, 1744, 1665, 1498, 1455, 1439, 1392, 1366, 
1248, 1163, 1072, 1025, 862, 735, 699, 461 cm-1; 1H-NMR (500 MHz, CDCl3) δ 7.35-7.28 (m, 5H), 
5.46 (d, J = 7.0), 4.65-4.62 (m, 1H), 4.54 (s, 2H), 4.32 (br s, 1H), 3.91-3.88 (m, 3H), 3.75 (s, 3H), 3.62 
(dd, J1 = 5.5, J2 = 9.5, 1H), 1.44 (s, 9H); 13C-NMR (125 MHz, CDCl3) δ 170.8, 170.7, 155.8, 137.5, 
128.7, 128.2, 128.1, 80.7, 73.7, 70.0, 63.0, 60.6, 55.2, 52.9, 28.5; HRMS (ESI-TOF) m/z: [M+Na]+ 
calculated for C19H28N2O7Na 419.1789, found 419.1791. 
N-Boc-Cys(Bn)-Ser-OMe (13). N-Boc-Cys(Bn)-OH (10.54 g, 34 mmol) and HOBt●H2O (5.03 g, 37 
mmoles, 1.1 eq) were dissolved into 100 mL of dry DMF and N,N′-diisopropylcarbodiimide (5.80 mL, 
37 mmol, 1.1 eq) was added and stirred at rt under N2 for 30 min, whereupon HCl●Ser-OMe (5.80 g, 37 
mmol, 1.1 eq) was added and the mixture sonicated in a bath sonicator. Triethylamine (30 mL, 216 
mmoles, 6.4 eq) was added to the reaction and stirred at rt under N2 for 2.5 h. White precipitate was 
removed from the reaction by filtration and washed with 50 mL of ethyl acetate. The combined filtrate 
was diluted into 500 mL of ethyl acetate and washed four times with 0.1 M citric acid (4 x 60 mL), 
saturated sodium bicarbonate (2 x 100 mL), brine (1 x 100 mL), dried over anhydrous MgSO4, and 
concentrated in vacuo. The crude material was dissolved into CH2Cl2 and loaded onto silica gel (350 
mL). The column wash washed with CH2Cl2, and the product eluted using a gradient of hexane:EtOAc 
from a ratio of 2:1 to 1:2, and combined fractions concentrated to yield 9.53 g (68%). Rf (hex-
ane/EtOAc, 1:1) 0.43; IR (neat) ν = 3306, 2979, 2364, 1744, 1657, 1517, 1454, 1437, 1366, 1245, 
1163, 1050, 1023, 864, 769, 736, 702, 561 cm-1; 1H-NMR (500 MHz, CDCl3) δ 7.36-7.29 (m, 5H), 
5.43 (d, J = 5.0, 1H), 4.61-4.58 (m, 1H), 4.24-4.21 (m, 1H), 3.90-3.88 (m, 2H), 3.72 (s, 3H), 3.71 (s, 
2H), 2.78 (d, J = 10.0, 2H), 1.40 (s, 9H); 13C-NMR (125 MHz, CDCl3) δ 171.8, 171.3, 156.3, 138.4, 
129.5, 129.1, 127.7, 80.8, 62.7, 55.0, 52.7, 42.33, 36.5, 33.6, 28.2; HRMS (ESI-TOF) m/z: [M+Na]+ 
calculated for C19H28N2O6SNa 435.1560, found 435.1556. 
N-Boc-Cys(Tr)-Ser-OMe (14). Following general procedure A on a 3.15 mmol scale of HCl●Ser-
OMe using Boc-Cys(Tr)-OH (1.50 g, 3.25 mmol), EDC (742.32 mg, 3.78 mmol), NMM (762 µl, 6.93 
mmol), and HOBt (65.20 mg, 0.47 mmol) in EtOH (20 ml), the desired product (1.59 g, 2.81 mmol, 
89%) was isolated as a white solid by silica gel column chromatography (hexane/EtOAc, 3:1): Rf (hex-
ane/EtOAc, 1:1) 0.43; IR (neat) ν = 3392, 3319, 3055, 2974, 2358, 2335, 1745, 1671, 1491, 1444, 
1391, 1367, 1248, 1166, 1030, 861, 743, 701, 627 cm-1; 1H-NMR (500 MHz, CDCl3) δ 7.29-7.21 (m, 
15H), 6.79 (d, J = 8.1, 1H), 4.77 (d, J = 5.7, 1H), 4.76-4.54 (m, 1H), 4.03 (dd, J1 = 2.7, J2 = 9.9, 1H), 
3.94 (m, 1H), 3.76 (dd, J1 = 3.0, J2 = 10.1, 1H), 3.69 (s, 3H), 2.78 (dd, J1 = 5.7, J2 = 13.2, 1H), 2.54 
(dd, J1 = 4.8, J2 = 12.6, 1H), 1.42 (s, 9H); 13C-NMR (125 MHz, CDCl3) δ 170.8, 170.6, 144.5, 129.8, 
128.4, 128.3, 127.2, 80.3, 67.5, 62.7, 55.3, 54.2, 52.9, 34.2, 28.5; HRMS (ESI-TOF) m/z: [M+Na]+ 
calculated for C31H36N2O6SNa 587.2186, found 587.2189. 
N-Boc-Ser(Bn)-Ser(TES)-OMe (15). Following general procedure B on a 0.63 mmol scale of 12 
using TES-Cl (316 µl, 1.89 mmol) and imidazole (129 mg, 1.89 mmol) in DMF (1 ml), the desired 
product (294 mg, 0.58 mmol, 91%) was isolated as a colorless oil by silica gel column chromatography 
(hexane/EtOAc, 9:1): Rf (hexane/EtOAc, 7:1) 0.25; IR (neat) ν = 3333, 2954, 2876, 2359, 2333, 1749, 
1717, 1680, 1497, 1456, 1366, 1247, 1206, 1167, 1109, 1047, 1017, 858, 743, 698 cm-1; 1H-NMR (500 
MHz, CDCl3) δ 7.34-7.29 (m, 5H), 5.39 (s, 1H), 4.67-4.64 (m, 1H), 4.58 (s, 2H), 4.35 (br s, 1H), 4.08 
(dd, J1 = 3.0,  J2 = 10.3, 1H), 3.89 (dd, J1 = 5.0, J2 = 9.3, 1H), 3.80 (dd, J1 = 3.5, J2 = 10.0, 1H), 3.72 (s, 
3H), 3.59 (dd, J1 = 6.5, J2 = 9.3, 1H), 1.45 (s, 9H), 0.90 (t, J = 7.5, 9H), 0.54 (q, J = 7.5, 6H); 13C-NMR 
(75 MHz, CDCl3) δ 170.7, 170.5, 155.6, 137.7, 128.6, 128.0, 127.9, 80.3, 73.7, 70.1, 63.4, 54.6, 54.0, 
52.5, 28.5, 6.8, 4.4; HRMS (ESI-TOF) m/z: [M+Na]+ calculated for C25H42N2O7SiNa 533.2654, found 
533.2653. 
N-Boc-Cys(Bn)-Ser(TES)-OMe (16). Following general procedure B on a 0.49 mmol scale of 13  
using TES-Cl (108 µl, 0.64 mmol) and imidazole (168 mg, 2.46 mmol) in DCM (5 ml), the desired 
product (167 mg, 0.32 mmol, 65%) was isolated as a white solid by silica gel column chromatography 
(hexane/EtOAc, 7:1): Rf (hexane/EtOAc, 7:1) 0.30; IR (neat) ν = 3286, 2953, 2874, 1743, 1710, 1673, 
1650, 1508, 1452, 1366, 1241, 1164, 1105, 1045, 1019, 1005, 869, 746, 733, 717, 699 cm-1; 1H-NMR 
(500 MHz, CDCl3) δ 7.36-7.23 (m, 5H), 7.12 (d, J = 7.5, 1H), 5.33 (br s, 1H), 4.61 (ddd, J1 = 5.5, J2 = 
6.0, J3 = 8.0, 1H), 4.32 (br s, 1H), 4.09 (dd, J1 = 2.5, J2 = 10.0, 1H), 3.82 (dd, J1 = 3.0, J2 = 10.3, 1H), 
3.78 (s, 2H), 3.73 (s, 3H), 2.87 (dd, J1 = 5.5, J2 = 14.0, 1H), 2.78 (dd, J1 = 7.0, J2 = 14.0, 1H), 1.46 (s, 
9H), 0.93 (t, J = 8.0, 9H), 0.57 (q, J = 8.0, 6H); 13C-NMR (100 MHz, CDCl3) δ 170.7, 170.6, 138.1, 
129.3, 128.8, 127.4, 77.4, 63.2, 54.7, 53.0, 52.6, 36.7, 34.2, 28.5, 6.8, 4.4; HRMS (ESI-TOF) m/z: 
[M+Na]+ calculated for C25H42N2O6SSiNa 549.2425, found 549.2432. 
N-Boc-Cys(Tr)-Ser(TES)-OMe (17). Following general procedure B on a 0.45 mmol scale of 14 
using TES-Cl (226 µl, 1.35 mmol) and imidazole (92 mg, 1.35 mmol) in DMF (1 ml): Rf (hex-
ane/EtOAc, 3:1), the desired product (274  mg, 0.40 mmol, 90%) was isolated as a white solid by silica 
gel column chromatography (hexane/EtOAc, gradient from 9:1 to 3:1): 0.71; IR (neat) ν = 3412, 3334, 
2954, 2912, 2876, 2361, 1748, 1716, 1672, 1490, 1444, 1366, 1248, 1207, 1167, 1110, 1047, 1016, 
862, 753, 700, 676, 618 cm-1; 1H-NMR (500 MHz, CDCl3) δ 7.35-7.28 (m, 5H), 5.46 (d, J = 7.0), 4.65-
4.62 (m, 1H), 4.54 (s, 2H), 4.32 (br s, 1H), 3.91-3.88 (m, 3H), 3.75 (s, 3H), 3.62 (dd, J1 = 5.5, J2 = 9.5, 
1H), 1.44 (s, 9H); 13C-NMR (75 MHz, CDCl3) δ 170.8, 170.7, 155.8, 137.5, 128.7, 128.2, 128.1, 80.7, 
73.7, 70.0, 63.0, 60.6, 55.2, 52.9, 28.5; HRMS (ESI-TOF) m/z: [M+Na]+ calculated for 
C37H50N2O6SSiNa 701.3051, found 701.3054.  
2-[(1S)-1-[[(1,1-Dimethylethoxy)carbonyl]amino]-2-(phenylmethoxy)ethyl]2-(4S)-oxazoline 
methyl ester (18). Following general procedure C on a 0.13 mmol scale of 12 using DAST (50 µl, 0.38 
mmol) at -78 °C and warming up to rt in CH2Cl2 (2 ml), the desired product (41 mg, 0.11 mmol, 85%) 
was isolated by silica gel column chromatography (hexane/EtOAc, 3:1): Rf (hexane/EtOAc, 1:1) 0.62; 
 +63.2 (c = 1.0, CHCl3); IR (neat) ν = 2971, 2360, 2334, 1741, 1713, 1664, 1498, 1458, 1366, 
1249, 1203, 1164, 1024, 971, 918, 862, 734, 698 cm-1; 1H-NMR (400 MHz, CDCl3) δ 7.28-7.20 (m, 
5H), 5.41 (d, J = 7.5, 1H), 4.71-4.69 (m, 1H), 4.55-4.37 (m, 6H), 3.72-3.63 (m, 5H), 1.36 (s, 9H); 13C-
NMR (100 MHz, CDCl3) δ 171.3, 168.6, 155.4, 138.0, 128.5, 127.9, 127.7, 80.1, 73.3, 70.3, 70.1, 68.2, 
52.9, 49.5, 28.5; HRMS (ESI-TOF) m/z: [M+H]+ calculated for C19H27N2O6 379.1864, found 
379.1863. 
2-[(1S)-1-[[(1,1-Dimethylethoxy)carbonyl]amino]-2-(thiobenzyl)ethyl]2-(4S)-oxazoline methyl 
ester (19). Following general procedure C on a 0.1 mmol scale of 13 using DAST (41 µl, 0.31 mmol) 
at -45 °C and warming up to rt in CH2Cl2 (2 ml), the desired product (25 mg, 0.061 mmol, 61%) was 
isolated by silica gel column chromatography (hexane/EtOAc, 3:1): Rf (hexane/EtOAc, 5:1) 0.21;  
+45.4 (c = 1.0, CHCl3); IR (neat) ν = 3391, 2979, 2920, 1742, 1713, 1662, 1496, 1454, 1366, 1332, 
1247, 1208, 1167, 1047, 1017, 766, 704 cm-1; 1H-NMR (400 MHz, CDCl3) δ 7.24-7.16 (m, 5 H), 5.35 
(d, J = 7.5, 1H), 4.73-4.68 (m, 1H), 4.62-4.59 (m, 1H), 4.51-4.47 (m, 1H), 4.41 (dd, J1 = 8.8, J2 = 10.6, 
1H), 3.71 (s, 3H), 3.66 (d, J = 1.5, 2H), 2.82 (dd, J1 = 5.3, J2 = 14.1, 1H), 2.73 (dd, J1 = 5.6, J2 = 14.0, 
1H), 1.37 (s, 9H); 13C-NMR (100 MHz, CDCl3) δ 171.1, 169.0, 155.1, 138.0, 129.1, 128.7, 127.3, 80.2, 
70.4, 68.1, 52.9, 48.7, 36.8, 34.5, 28.5; HRMS (ESI-TOF) m/z: [M+Na]+ calculated for 
C19H26N2O5SNa 417.1455, found 417.1459. 
2-[(1S)-1-[[(1,1-Dimethylethoxy)carbonyl]amino]-2-((triphenylmethyl)thio)ethyl]2-(4S)-
oxazoline methyl ester (20). Following general procedure C on a 0.09 mmol scale of 14 using DAST 
(37 µl, 0.28 mmol) at -78 °C and warming up to rt in CH2Cl2 (2 ml), the desired product (40 mg, 0.07 
mmol, 79%) was isolated by silica gel column chromatography (hexane/EtOAc, 3:1): Rf 
(hexane/EtOAc, 3:1) 0.27;  + 48.5 (c = 1.0, CHCl3); IR (neat) ν = 2976, 2361, 1743, 1715, 1661, 
1491, 1444, 1366, 1265, 1248, 1209, 1165, 1035, 981, 964, 849, 767, 738, 700, 676, 620 cm-1; 1H-
NMR (400 MHz, CDCl3) δ 7.33-7.30 (m, 6H), 7.21-7.11 (m, 9H)5.09 (br s, 1H), 4.68-4.64 (m, 1H), 
4.48-4.31 (m, 2H), 3.67 (s, 3H), 2.52(d, J = 5.4, 2H), 1.34 (s, 9H); 13C-NMR (100 MHz, CDCl3) δ 
171.2, 168.9, 154.9, 144.6, 129.7, 128.1, 127.0, 80.1, 70.4, 68.1, 66.9, 52.8, 48.1, 35.2, 28.5; HRMS 
(ESI-TOF) m/z: [M+Na]+ calculated for C31H34N2O5SNa 569.2081, found 569.2086. 
N-Boc-Ser(Bn)-Ser-Ser-OMe (21). To a stirring solution of 12 (1.72 g, 4.35 mmol) at rt in MeOH 
(30 ml) was added a solution of LiOH (625.20 mg, 26.09 mmol) in H2O (15 ml) and stirred for 4 h. 
After completion, approximately 2/3 of the MeOH was removed by a rotary evaporator. The solution 
was then acidified by adding 40 ml of 1M NaHSO4 whereon a white precipitate was formed. The sus-
pension was extracted with EtOAc (3x) and the combined organic phases were dried with MgSO4, fil-
tered, and evaporated in vacuo to yield the carboxylic acid (1.60 g, 4.11 mmol, 96 %) as a white solid. 
The crude material was directly used for peptide bond formation. To individual stirring solutions of the 
carboxylic acid (1.55 g, 4.05 mmol) and HCl●Ser-OMe (630.62 mg, 4.05 mmol) DMF was added (each 
20 ml) and NMM (each 1.23 ml, 12.16mmol).PyBop (3.17 g, 6.08 mmol) was added to the stirring 
solution of carboxylic acid, followed by the solution of H-Ser-OMe. The reaction solution was stirred 
over night at rt. After completion, most of the DMF was removed on a rotary evaporator, diluted with 
EtOAc (30 ml), washed with 0.1 M citric acid (2x), sat. NaHCO3 (2x), and brine, dried over MgSO4, 
filtered, and evaporated in vacuo. The crude material was purified by column chromatography (gradi-
ent from 0 to 10 % MeOH in CHCl3) to give 21 (1.09 g, 2.25 mmol, 56%) as a mixture of four di-
astereomers: Rf  (CHCl3/MeOH, 9:1) 0.31; 1H-NMR (500 MHz, CDCl3) δ 7.35-7.28 (m, 20H), 5.62-
5.52 (m, 4H), 4.60-4.56 (m, 8H), 4.29 (br-s, 4H), 4.08-3.82 (m, 16H), 3.75-3.73 (m, 12H), 3.69-3.66 
(m, 8H), 1.42 (s, 36H); 13C-NMR (100 MHz, CDCl3) δ 171.4, 171.3, 170.9, 170.8, 137.5, 137.4, 137.4, 
137.4, 173.4, 137.3, 128.8, 128.8, 128.7, 128.4, 128.3, 128.2, 128.2, 128.1, 128.1, 128.1, 128.1, 81.2, 
73.8, 73.7, 73.6, 62.9, 62.6, 62.5, 62.5, 56.0, 55.3, 55.3, 54.8, 53.1, 53.0, 53.0, 52.9, 46.7, 28.5, 28.5, 
28.5, 28.4, 26.6, 26.5, 26.5, 26.4; HRMS (ESI-TOF) m/z: [M+Na]+ calculated for C22H33N3O9Na 
506.2109, found 506.2105. 
N-Boc-Ser(Bn)-Ser(TES)-Ser(TES)-OMe (22). Following general procedure B on a 0.59 mmol 
scale of 21  using TES-Cl (498 µl, 2.96 mmol) and imidazole (243 mg, 3.56 mmol) in DMF (2 ml), the 
desired product (344 mg, 0.48 mmol, 85%) was isolated as a mixture of four diastereomers as a 
colorless oil by column chromatography (hexane/EtOAc, 5:1): Rf (hexane/EtOAc, 3:1) 0.43; 1H-NMR 
(500 MHz, CDCl3) δ 7.35-7.28 (m, 20H), 0.83 (s, 4H), 4.68-4.65 (m, 4 H), 4.62-4.51 (m, 8H), 4.48-
4.43 (m, 4H), 4.32 (br s, 4H), 4.07-4.02 (m, 8H), 3.90-3.77 (m, 8H), 3.73-3.71 (m, 12H), 3.62-3.56 (m, 
8H), 1.44 (s, 36H), 0.98-0.89 (m, 72H), 0.66-0.55 (m, 48H); 13C-NMR (100 MHz, CDCl3) δ 170.5, 
170.4, 170.3, 170.3, 170.3, 170.2, 169.9, 169.9, 169.8, 155.5, 137.5, 128.5, 128.5, 128.4, 128.4, 128.4, 
127.8, 127.8, 127.8, 127.8, 127.7, 127.7, 73.4, 73.4, 73.3, 69.9, 69.8, 69.6, 69.6, 63.3, 63.2, 54.6, 54.6, 
54.4, 54.4, 54.3, 54.3, 54.3, 54.2, 28.3, 28.2, 28.3, 6.7, 6.6, 6.6, 4.2, 4.2; HRMS (ESI-TOF) m/z: 
[M+Na]+ calculated for C34H61N3O9Si2Na 734.3839, found 734.3834. 
2-[(1S)-1-[[(1,1-Dimethylethoxy)carbonyl]amino]-2-(phenylmethoxy)ethyl]2-[2,4':2',4'']-bis-
oxazoline methyl ester (23). Following general procedure C on a 0.07 mmol scale of 21 using DAST 
(53 µl, 0.40 mmol) at -78°C and warming up to rt in CH2Cl2 (2 ml), the desired product (16 mg, 0.04 
mmol, 53 %) was isolated by silica gel column chromatography (1% MeOH in CHCl3) as a mixture of 
four diastereomers: Rf (1 % MeOH in CHCl3) 0.50; 1H-NMR (500 MHz, CDCl3) δ 7.34-7.28 (m, 20H), 
6.52 (d, J = 9.5, 4H), 5.64 (d, J = 7.5, 4H), 5.45 (s, 4H), 4.83-4.73 (m, 4H), 4.65-4.50 (m, 20H), 4.65 (s, 
4H), 3.95 (s, 4H), 3.80-3.72 (m, 12H), 3.63-3.57 (m, 8H), 1.46-1.45 (m, 36H); 13C-NMR (100 MHz, 
CDCl3) δ 172.5, 172.0, 171.9, 171.9, 171.8, 171.3, 171.2, 169.5, 169.2, 169.1, 169.0, 168.9, 168.8, 
138.0, 137.9, 129.0, 129.0, 129.0, 128.9, 128.8, 128.4, 128.4, 128.3, 128.2, 128.1, 128.0, 128.0, 81.1, 
80.7, 73.6, 73.5, 70.5, 70.4, 70.2, 68.1, 68.0, 67.7, 54.6, 54.5, 53.5, 52.6, 52.6, 52.5, 49.9, 49.9, 49.7, 
49.4, 49.4, 28.2, 28.2, 28.2, 28.1; HRMS (ESI-TOF) m/z: [M+Na]+ calculated for C22H29N3O7Na 
470.1898, found 470.1897. 
N-Boc-Ser-OMe (24). To stirring solution of H-Ser-OMe●HCl (10 g, 64.3 mmol) at rt in CH2Cl2 
(150 ml) was added Et3N (20 ml, 140 mmol) and the resulting suspension was cooled to 0°C in an ice 
bath. After 30 min, Boc2O (15.5 g, 71 mmol) was added and the suspension was stirred over night 
while slowly warming to rt. After completion, the suspension was diluted with CH2Cl2 and washed 
with 1 M NaHSO4 (3x), sat. NaHCO3 (1x), and brine (1x). All aq. layers were back extracted with 
CH2Cl2 and the comb. org. layers were dried over MgSO4, filtered, and evaporated in vacuo to give 24 
as a colorless oil (14.31 g, 65.3 mmol, 99%). Rf (hexane/EtOAc, 3:1) 0.10; IR (neat) ν = 3412, 2979, 
2364, 1743, 1693, 1506, 1458, 1438, 1392, 1367, 1350, 1249, 1210, 1159, 1059, 1030, 853, 780, 736, 
702 cm-1; 1H-NMR (300 MHz, CDCl3) δ 5.49 (br s, 1 H), 4.40 (br s, 1 H), 3.94 (dd, J1 = 10.1, J2 = 3.7, 
2 H), 3.79 (s, 3 H), 1.45 (s, 9 H); 13C-NMR (75 MHz, CDCl3) δ171.2; 155.7; 80.3, 63.5, 55.6; 52.6; 
28.2; HRMS (ESI-TOF) m/z: [M+Na]+ calculated for C9H17NO5Na 242.0999, found 242.1003.  
N-[(Phenlymethoxy)carbonyl]-(S)-serine methyl ester (25). To a stirring solution of HCl●Ser-
OMe (458 mg, 2.95 mmol) at rt in H2O/MeOH (8:3, 5.5 ml) was added NaHCO3 (744 mg, 8.84 mmol) 
and cooled to 0 °C. Benzyl chloroformate (505 µl, 3.54 mmol) was added to yield a white suspension 
that was slowly warmed to rt and then refluxed at 70 °C for 6 h. The reaction mixture was allowed to 
cool to rt, diluted with sat. NaHCO3, extracted with EtOAc (3x), dried over MgSO4, filtered, and 
evaporated in vacuo. The crude material was purified by column chromatography on silica gel (hex-
ane/EtOAc, 3:1) to give 25 as a white solid (535 mg, 2.11 mmol, 72%): Rf (hexane/EtOAc, 1:1) 0.30; 
IR (neat) ν = 3426, 2956, 2361, 1703, 1516, 1450, 1341, 1266, 1210, 1059, 1028, 97, 733, 697, 474 
cm-1; 1H-NMR (300 MHz, CDCl3) δ 7.36-7.31 (m, 5H), 5.78 (d, J = 6.9, 1H), 5.12 (s, 2H), 4.47-4.42 
(m, 1H), 3.99 (dd, J1 = 3.6, J2 = 11.1, 1H), 3.90 (dd, J1 = 3.3, J2 = 11.1, 1H), 3.77 (s, 3H); 13C-NMR 
(75 MHz, CDCl3) δ 171.3, 156.4, 136.2, 128.8, 128.5, 128.3, 67.4, 63.4, 56.2, 53.0; HRMS (ESI-TOF) 
m/z: [M+Na]+ calculated for C12H15NO5Na 276.0842, found 276.0839. 
N-[(Phenlymethoxy)carbonyl]-O-(triethylsilyl)-(S)-serine methyl ester (26). Following general 
procedure B on a 0.46 mmol scale of 25 using TES-Cl (233 µl, 0.1.39 mmol) and imidazole (96 mg, 
1.39 mmol) in DMF (1 ml), the desired product (86 mg, 0.23 mmol, 51%) was isolated as a colorless 
oil by silica gel column chromatography (hexane/EtOAc, 7:1): Rf (hexane/EtOAc, 3:1) 0.49; IR (neat) 
ν = 2954, 2877, 2361, 1725, 1505, 1456, 1438, 1381, 1343, 1297, 1239, 1203, 1174, 1109, 1084, 1063, 
1028, 1005, 979, 821, 732, 697 cm-1; 1H-NMR (300 MHz, CDCl3) δ 7.34-7.31 (m, 5H), 5.73 (d, J = 
8.4, 1H), 5.13 (d, J = 2.4, 2H), 4.44-4.40 (m, 1H), 4.07 (dd, J1 = 2.7, J2 = 10.1, 1H), 3.84 (dd, J1 = 3.0, 
J2 = 10.1, 1H), 3.75 (s, 3H), 0.91 (t, J = 8.1, 9H), 0.54 (q, J = 7.8, 6H); 13C-NMR (100 MHz, CDCl3) δ 
171.2, 156.2, 136.5, 128.7, 128.4, 128.3, 67.2, 63.5, 56.2, 52.6, 6.7, 4.4; HRMS (ESI-TOF) m/z: 
[M+Na]+ calculated for C18H29NO5Na 390.1707, found 390.1709. 
N-[(9-Fluorenylmethoxy)carbonyl]-(S)-serine methyl ester (27). To a stirring solution of 
HCl●Ser-OMe (316 mg, 2.03 mmol) at rt in H2O/MeOH (8:3, 5.5 ml) was added NaHCO3 (512 mg, 
6.10 mmol) and cooled to 0 °C. At 0 °C, Fmoc-Cl (632 mg, 2.44 mmol) was added to give a white sus-
pension that was slowly warmed to rt and then refluxed overnight at 70 °C. The reaction mixture was 
allowed to cool to rt, diluted with sat. NaHCO3, extracted with EtOAc (3x), dried over MgSO4, filtered, 
and evaporated in vacuo. The crude material was purified by column chromatography on silica gel 
(hexane/EtOAc, 3:1) to give 27 as a white solid (350 mg, 1.03 mmol, 51%): Rf (hexane/EtOAc, 1:1) 
0.36; IR (neat) ν = 3412, 3061, 2950, 2868, 2354, 2334, 1704, 1519, 1449, 1338, 1265, 1209, 1104, 
1057, 976, 759, 735, 702, 621, 568, 534, 519, 507, 426 cm-1; 1H-NMR (300 MHz, CDCl3) δ 7.60-7.30 
(m, 8H), 5.81 (d, J = 7.5, 1H), 4.46-4.24 (m, 3H), 4.22 (t, J = 7.0), 4.00 (dd, J1 = 2.5, J2 = 11.0, 1H), 
3.91 (dd, J1 = 2.5, J2 = 11.5, 1H), 3.78 (s, 3H); 13C-NMR (125 MHz, CDCl3) δ 171.2, 156.5, 144.0, 
143.8, 141.5, 141.5, 128.0, 127.3, 127.3, 125.3, 120.2, 120.2, 67.4, 63.4, 56.8, 53.0, 47.3; HRMS (ESI-
TOF) m/z: [M+Na]+ calculated for C19H19NO5Na 364.1155, found 364.1152. 
N-[(9-Fluorenylmethoxy)carbonyl]-O-(triethylsilyl)-(S)-serine methyl ester (28). Following 
general procedure B on a 0.28 mmol scale of 27 using TES-Cl (138 µl, 0.82 mmol) and imidazole (57 
mg, 0.82 mmol) in DMF (1.5 ml), the desired product (64 mg, 0.14 mmol, 51%) was isolated as a 
colorless oil by silica gel column chromatography (hexane/EtOAc, 7:1): Rf (hexane/EtOAc, 3:1) 0.69; 
IR (neat) ν = 2955, 2876, 2361, 1722, 1506, 1449, 1341, 1242, 1204, 1106, 1082, 1059, 1006, 979, 
756, 736, 543 cm-1; 1H-NMR (300 MHz, CDCl3) δ 7.60-7.29 (m, 8H), 5.69 (d, J = 8.7), 4.47-4.41 (m, 
1H), 4.37 (d, J = 6.9, 1H), 4.26 (t, J = 7.2, 1H), 4.10 (dd, J1 = 2.7, J2 = 10.4, 1H), 3.88 (dd, J1 = 3.3, J2 
= 10.2, 1H), 3.77 (s, 3H), 0.95 (t, J = 7.9, 9H), 0.59 (q, J = 8.1, 6H); 13C-NMR (75 MHz, CDCl3) δ 
171.0, 156.0, 143.8, 141.3, 127.7, 127.1, 125.2, 125.1, 120.0, 67.2, 63.4, 56.0, 52.4, 47.1, 6.6, 4.2; 
HRMS (ESI-TOF) m/z: [M+Na]+ calculated for C25H33NO5SiNa 478.2020, found 478.2019. 
 (4S)-4-Methoxycarbonyl-2-benzyloxy-2-oxazoline (30). Following general procedure C on a 0.11 
mmol scale of 25 using XtalFluor-E (50 mg, 0.22 mmol) at -78°C and warming up to rt in CH2Cl2 (2 
ml), the desired product (5 mg, 0.02 mmol, 16%) was isolated by silica gel column chromatography 
(hexane/EtOAc, 3:1): Rf (hexane/EtOAc, 5:1) 0.21; IR (neat) ν = 1740, 1438, 1414, 1363, 1217, 1202, 
1176, 1090, 1062, 1030, 1001, 937, 758, 741,701, 672, 593, 457 cm-1; 1H-NMR (300 MHz, CDCl3) δ 
7.35-7.24 (m, 5H), 4.90 (d, J = 15.0, 1H), 4.44-4.38 (m, 1H), 4.34 (dd, J1 = 4.8, J2 = 8.9, 1H), 4.24 (d, J 
= 15, 1H), 4.10 (dd, J1 = 5.1, J2 = 9.5, 1H), 3.74 (s, 3H); 13C-NMR (100 MHz, CDCl3) δ 170.7, 158.3, 
135.6, 129.5, 129.1, 128.8, 64.5, 56.0, 52.9, 47.4; HRMS (ESI-TOF) m/z: [M+Na]+ calculated for 
C12H13NO4Na 258.0737, found 258.0734.  
(4S)-2-(9-Fluorenylmethoxy)-4-methoxycarbonyl-2-oxazoline (31). Following general procedure 
C on a 0.11 mmol scale of 27 using DAST (44 µl, 0.33 mmol) at -78°C and warming up to rt in CH2Cl2 
(2 ml), the desired product (21 mg, 0.07 mmol, 61%) was isolated by silica gel column 
chromatography (hexane/EtOAc, 3:1): Rf (hexane/EtOAc, 3:1) 0.31; IR (neat) ν = 1742, 1660, 1477, 
1449, 1404, 1354, 1306, 1249, 1209, 1181, 1100, 1059, 964, 760, 742 cm-1; 1H-NMR (300 MHz, 
CDCl3) δ 7.77 (d, J = 9, 2H), 7.63 (d, J = 9, 2H), 7.43-7.38 (m, 2H), 7.34-7.29 (m, 2H), 4.70-4.52 (m, 
5H), 4.34 (t, J = 9, 1H), 3.77 (s, 3H); 13C-NMR (75 MHz, CDCl3) δ 172.2, 164.8, 143.4, 143.3, 141.5, 
128.1, 127.3, 125.5, 120.2, 73.4, 70.5, 65.4, 52.8, 46.8; HRMS (ESI-TOF) m/z: [M+Na]+ calculated for 
C19H17NO4Na 346.1050, found 346.1051. 
Solid phase synthesis of TFA.H2N-[Ser]5-OH (32). Fmoc-Ser(OtBu)-OH (2.36 g, 6.14 mmol) and 
DIEA (2.09 ml, 12.28 mmol) in CH2Cl2 (30 ml) were stirred at rt for 5 min. The solution was added to 
a pre-activated and swelled 2-chlorotrityl chloride resin (8.19 g), which was agitated at rt for 4.5 h. The 
resin was washed with CH2Cl2 (3 x 30 ml), DMF (3 x 30 ml), and CH2Cl2 (3 x 30 ml). Unreacted resin 
positions were capped by adding a solution of CH2Cl2:MeOH:DIEA (80:15:5, 3 x 30 ml), which was 
agitated at rt for 3 x 10 min. The resin was then washed with CH2Cl2 (4 x 30 ml) and dried over KOH 
in vacuo.  A solution of 25 % piperidine in DMF (6 x 15 ml) was added to the resin, which was agi-
tated for 6 x 10 min. The resin was then washed with DMF (3 x 30 ml), CH2Cl2 (2 x 30 ml), and DMF 
(2 x 30 ml). Fmoc-Ser(OtBu)-OH (3.64 g, 9.51 mmol), DIEA (4.04 ml, 23.76 mmol), HOBt (1.25 g, 
9.27 mmol), and HBTU (3.52 g, 9.27 mmol) were dissolved in DMF (30 ml) at rt and stirred for 10 
min. The solution was added to the pre-swelled resin which was agitated at rt for 4.5 h. The resin was 
then washed with DMF (5 x 30 ml) and dried in vacuo. Fmoc deprotection of resin bound dipeptide 
and loading of Fmoc-Ser(OtBu)-OH were then repeated three times. Fmoc-removal was carried out 
using piperidine as described above. A solution of TFA:H2O:TIS (95:2.5:2.5, 40 ml) was added to the 
resin and agitated at rt for 2 h. The resin was filtered off and the pentapeptide 32 was precipitated by 
adding diisopropyl ether (-20 °C) to the filtrate. The peptide was centrifuged, washed with Et2O (3x) 
and dried in vacuo. The peptide was redissolved in a solution of H2O/CH3CN (2:1, 10 ml) and lyophi-
lized to give crude 32 (2.26 g, 3.99 mmol, 84%) as a slightly yellow powder. The crude peptide was 
used without further purification. 1H-NMR (500 MHz, DMSO-d6) δ 8.58 (d, J = 7.5, 1H), 8.06 (d, J = 
7.5, 1H), 7.98-7.94 (m, 2H),  4.49 – 4.45 (m, 1H), 4.40-4.35 (m, 2H), 4.27-4.24 (m, 1H), 3.92-3.90 (m, 
1H), 3.71-3.56 (m, 10H); 13C-NMR (125 MHz, CDCl3) δ 171.6, 171.4, 171.3, 170.9, 170.5, 68.2, 62.5, 
62.3, 61.7, 61.2, 58.9, 57.9, 57.4, 56.4, 55.7, 55.4; HRMS (ESI-TOF) m/z: [M – TFA + H]+ calculated 
for C15H28N5O11 454.1780, found 454.1781. 
N-Fmoc-[Ser]5-OMe (33). To a stirring solution of 32 (205 mg, 0.36 mmol) at rt in H2O/MeOH 
(8/3) was added NaHCO3 (121 mg, 1.44 mmol) and Fmoc-Cl (121 mg, 0.47 mmol) and the resulting 
mixture was refluxed at 70°C over night. The reaction mixture was then dried down, transferred to a 50 
ml falcon tube, washed and centrifuged with DCM (2x). After drying in vacuo, the crude material was 
suspended in MeOH (10 ml) at rt and TMS-Cl (916 µl, 7.22 mmol) was added dropwise. The reaction 
mixture was stirred over night and diluted with Et2O (50 ml). The precipitate was collected by centri-
fuged, washed with Et2O (3x), and dried in vacuo. The crude material was suspended in pyridine (5 ml) 
at rt and TES-Cl (909 µl, 5.42 mmol) was added dropwise and stirred over night. The reaction mixture 
was diluted with EtOAc and washed with 0.1 M citric acid (2x), brine (2x), dried over MgSO4, filtered, 
and dried by rotary evaporator. The remaining pyridine was removed by coevaporation with toluene (2 
x 5 ml). The crude material was purified by silica gel column chromatography (hexane/EtOAc, gradi-
ent from 7:1 to 4:1) to give 33 (100 mg, 0.079 mmol, 22%) as a white solid: Rf (hexane/EtOAc, 5:1) 
0.21; IR (neat) ν = 3299, 2954, 2911, 2876, 2361, 2333, 1753, 1636, 1512, 1463, 1239, 1112, 1037, 
1007, 973, 811, 738, 668 cm-1; 1H-NMR (500 MHz, DMSO-d6) δ 8.58 (d, J = 7.5, 1H), 8.06 (d, J = 7.5, 1H), 
7.98-7.94 (m, 2H),  4.49 – 4.45 (m, 1H), 4.40-4.35 (m, 2H), 4.27-4.24 (m, 1H), 3.92-3.90 (m, 1H), 3.71-3.56 (m, 
10H); 13C-NMR (125 MHz, CDCl3) δ 170.2, 169.7, 169.6, 169.5, 169.5, 169.5, 141.3, 141.3, 127.7, 
127.1, 125.2, 125.2, 120.0, 72.6, 63.6, 63.2, 62.7, 62.5, 55.1, 54.8, 54.6, 52.5, 47.5, 7.1, 7.1, 7.1, 7.1, 
7.0, 6.3, 4.7, 4.7, 4.6, 4.6; HRMS (ESI-TOF) m/z: [M+Na]+ calculated for C61H109N5O13Si5Na 
1282.6760, found 1282.6760. 
2-(9-Fluorenylmethyl)-[2,4':2',4'':2'',4''':2''',4'''']-pentoxazoline methyl ester (34). To a stirring 
solution of 33 (36 mg, 0.029 mmol) in CH2Cl2 at -78 °C was added DAST (43 µl, 0.33 mmol). The 
reaction was stirred for 4 h, while being slowly warmed to 0 °C. The reaction was quenched using 
MeOH and the solvent was removed by rotary evaporator. The crude material was subjected to silica 
gel column chromatography (2 % MeOH in CHCl3) to give 34 as a single diastereoisomer (5.9 mg, 
0.010 mmol, 34%): 1H-NMR (500 MHz, CDCl3) δ 7.77 (d, J = 7.5, 2H), 7.60 (t, J = 7.5, 2H), 7.49 (d, J 
= 8.0, 1H), 7.39 (t, J = 7.5, 2H), 7.31 (t, J = 7.5, 2H), 5.76 (s, 1H), 4.70-4.67 (m, 1H), 4.42-4.38 (m, 
4H), 4.25-4.22 (m, 2H), 4.07-4.02 (m, 4H), 3.99 (dd, J1 = 4.5, J2 = 9.5, 1H), 3.78 (dd, J1 = 3.5, J2 = 
10.0, 1H), 3.72 (s, 3H), 3.69-3.65 (m, 2H,), 3.58-3.55 (m, 2H), 0.99-0.90 (m, 45H), 0.69-0.53 (m, 30H); 
13C-NMR (125 MHz, CDCl3) δ 144.5, 141.8, 141.5, 132.4, 127.8, 127.3, 124.9, 120.3, 110.2, 71.2, 
70.5, 68.1, 65.4, 63.3, 52.9, 50.6, 47.0, 29.9, 27.5; HRMS (ESI-TOF) m/z: [M+Na]+ calculated for 
C31H29N5O8Na 622.1908, found 622.1909. 
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